IL-33

Product Information
Primary Accession	O95760
Species	Human
Sequence	Ser112-Thr270
Purity	> 95% as analyzed by SDS-PAGE
Endotoxin Level	< 0.2 EU/ µg of protein by gel clotting method
Biological Activity	ED₅₀ < 0.5 ng/ml, measured by a cell proliferation assay using D10S cells, corresponding to a specific activity of > 2.0 × 10⁶ units/mg.
Expression System	E. coli
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 µg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Additional Information
Other Names	Interleukin-33, IL-33, Interleukin-1 family member 11, IL-1F11, Nuclear factor from high endothelial venules, NF-HEV, Interleukin-33 (95-270), Interleukin-33 (99-270), Interleukin-33 (109-270), IL33 (HGNC:16028), C9orf26, IL1F11, NFHEV
Target Background	Interleukin-33 (IL-33) is a proinflammatory cytokine that belongs to the IL-1 family. IL-33 is expressed in a variety of cells, including epithelial and endothelial cells, smooth muscle cells, macrophages and fibroblasts. The primary receptors for IL-33 are ST2 and IL-1 receptor accessory protein (IL-1RAcP), both of which belong to the IL-1 receptor family. IL-33 is localized to the nucleus of resting cells where it binds to chromatin in the H2A-H2B histone complex as a transcriptional suppressor. IL-33 is secreted by cells during injury which induces a T-helper 2 type inflammatory response. Evidence suggests IL-33 plays a role in autoimmune disease. IL-33’s interaction with ST2 can drive allergic pathology and IL-33 has been reported to play a role in the development of rheumatoid arthritis and systemic lupus erythematosus.